Gil-Nagel, A.
233  results:
Search for persons X
?
4

Retrospective study of perampanel efficacy and tolerability..:

Gil-López, F. J. ; Montoya, J. ; Falip, M....
Acta Neurologica Scandinavica.  138 (2018)  2 - p. 122-129 , 2018
 
?
6

Efficacy of eslicarbazepine acetate as adjunctive therapy o..:

Gil-Nagel, A. ; Elger, C. ; Ben-Menachem, E....
Journal of the Neurological Sciences.  333 (2013)  - p. e43 , 2013
 
?
7

Tolerability of eslicarbazepine acetate as adjunctive thera..:

Elger, C. ; Ben-Menachem, E. ; Gil-Nagel, A....
Journal of the Neurological Sciences.  333 (2013)  - p. e43-e44 , 2013
 
?
8

Perampanel, a Selective, Non-Competitive AMPA Receptor Anta..:

Laurenza, A. ; French, J. ; Gil-Nagel, A....
Neurology.  78 (2012)  Meeting Abstracts 1 - p. S56.005-S56.005 , 2012
 
?
9

Perampanel, a Selective, Non-Competitive AMPA Receptor Anta..:

Laurenza, A. ; French, J. ; Gil-Nagel, A....
Neurology.  78 (2012)  Meeting Abstracts 1 - p. IN5-1.004-IN5-1.004 , 2012
 
?
10

Does Geographic Region Impact the Efficacy of Ezogabine/Ret..:

Burdette, D. ; Gil-Nagel, A. ; Scott, A....
Neurology.  78 (2012)  Meeting Abstracts 1 - p. P06.123-P06.123 , 2012
 
?
 
?
15

Efficacy and safety of 800 and 1200 mg eslicarbazepine acet..:

Gil-Nagel, A. ; Lopes-Lima, J. ; Almeida, L....
Acta Neurologica Scandinavica.  120 (2009)  5 - p. 281-287 , 2009
 
1-15